<DOC>
	<DOCNO>NCT02196701</DOCNO>
	<brief_summary>The purpose study determine safety efficacy use combination therapy adalimumab ( ADA ) every week ( EOW ) methotrexate ( MTX ) suboptimal responder ADA monotherapy .</brief_summary>
	<brief_title>Concomitant Longitudinal Evaluation Adalimumab With Methotrexate Real World : CLEAR Study</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subjects ADA monotherapy ( 40 mg eow great ) least 16 week opinion Investigator show suboptimal response treatment PGA &gt; 3 PASI &gt; 5 ; Subjects initial positive response ADA monotherapy ( 40 mg eow great ) fail maintain optimal level response , base opinion Investigator , PGA &gt; 3 PASI &gt; 5 ; 2 . Subjects receive 40 mg ADA weekly must ADA 40 mg eow 8 week prior screen ; 3 . Subjects least 6 month history chronic plaque Ps ; 4 . Subjects great equal 18 year age ; 5 . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile childbearing potential practice birth control ; 6 . The result serum pregnancy test perform Screening Period urine pregnancy test perform Baseline Visit must negative ; 7 . Subject judge good general health determine Principal Investigator ; 8 . Subjects must evaluate latent TB infection ; 9 . Subjects must able willing provide write informed consent comply requirement study protocol ; 10 . Subjects must willing able selfadminister subcutaneous ( SC ) injection qualify person available administer SC injection . 1 . Subject contraindication MTX ADA ; 2 . Subject previous fail response poor tolerance ADA ; 3 . Subject poorly control medical condition , opinion Investigator , would put subject risk participation study ; 4 . Subject history clinically significant hematologic , renal liver disease ; 5 . Subject history neurologic symptom suggestive central nervous system ( CNS ) demyelinate disease and/or diagnosis central demyelinate disease ; 6 . Subject evidence dysplasia history malignancy ( include lymphoma leukemia ) successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma localize carcinoma situ cervix ; 7 . Subject history listeriosis , histoplasmosis , untreated TB , persistent chronic infection , recent active infection require hospitalization treatment intravenous ( iv ) antiinfectives within 30 day oral antiinfectives within 14 day prior Baseline visit ; 8 . Subject know immune deficiency , history HIV immunocompromised ; 9 . Subject currently use plan use antiretroviral therapy time study ; 10 . Female subject pregnant breastfeeding consider become pregnant study 150 day last dose study medication ; 11 . Subject history clinically significant drug alcohol usage last year maintain alcohol intake 30 g day less throughout study ( one standard drink define 180 mL/6 oz ( approx . 10 g ) wine , 360 mL/12 oz ( approx . 15 g ) regular beer , 45 mL/1.5 oz ( approx . 10 g ) spirit ; 12 . Screening clinical laboratory analyse show follow abnormal laboratory result : Aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; 2x upper limit normal ( ULN ) ; Serum total bilirubin &gt; 1.5 mg/dL ( &gt; 26 micromol/L ) , except subject Gilbert 's Syndrome ; Creatinine &gt; 1.5 mg/dL ( 133 micromol/L ) subject ≤ 65 year old &gt; upper limit normal range subject &gt; 65 ; Positive Hepatitis B C serology indicative previous current infection . 13 . Subject consider Investigator , reason , unsuitable candidate study ; 14 . The following treatment prohibit subject study : 1 . Phototherapy ( PUVA ( within 4 week Baseline Visit ) and/or UVB ( within 2 week Baseline Visit ) ; 2 . Other biologic therapy ( include antiTNF ) within 4 week Baseline Visit ; 3 . Any investigational agent chemical biologic nature within minimum 30 day 5 halflives ( whichever longer ) drug prior Baseline visit ; 4 . Any systemic drug therapy Ps within 4 week Baseline Visit ; 5 . Oral injectable corticosteroid , new prescription topical therapy , change concentration current prescription topical therapy ( include corticosteroid ) use , within 2 week Baseline Visit . Subjects may continue use previously prescribe topical therapy ( include corticosteroid ) study . 15 . Prior exposure biologics potential know association Progressive multifocal leukoencephalopathy PML ( i.e. , natalizumab ( Tysabri® ) rituximab ( Rituxan® ) ) ; 16 . Subjects active viral infection base investigator 's clinical assessment make subject unsuitable candidate study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>methotrexate</keyword>
	<keyword>adalimumab</keyword>
	<keyword>biologic</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Tumor necrosis factor ( TNF ) -α inhibitor</keyword>
</DOC>